What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of human embryonic stem cell-derived hepatocytes for treating acute liver failure.

March 25, 2026Stem Cell Research & Therapy0 citationsOpen Access

Preclinical efficacy and safety evaluation of human embryonic stem cell-derived functional hepatocytes for a clinical trial in acute liver failure

YSYi SunCentral South University JYJuan YuNational Engineering Research Center of Human Stem Cells YSYang ShiNational Engineering Research Center of Human Stem Cells

Key Points

This research aims to evaluate the efficacy and safety of human embryonic stem cell-derived hepatocytes for treating acute liver failure.
Developed a GMP-compliant process for differentiation of hESCs into hepatocytes
Assessed the functions of resulting hepatocyte-like cells (HPLCs)
Evaluated therapeutic efficacy in an animal model of acute liver failure
Conducted biosafety assessments of HPLCs
HPLCs exhibited robust hepatocyte functions
Demonstrated therapeutic efficacy in the ALF animal model
Favorable biosafety profiles were observed

Abstract

A novel multistage, GMP-compliant process was developed for the effective and reproducible differentiation of hESCs into hepatocytes. The resulting HPLCs demonstrated robust hepatocyte functions, therapeutic efficacy in an ALF animal model, and favorable biosafety profiles. These findings support the clinical translation of HPLCs, with an ongoing Phase I clinical trial designed to evaluate their safety and feasibility in patients with ALF and ACLF.

KI fragen

Bookmark

View Full Paper